Tebbe U, Messer C, Stammwitz E, The G S, Dietl J, Bischoff K-O, Schulten-Baumer U, Tebbenjohanns J, Gohlke H, Bramlage P
Klinikum Lippe GmbH, Fachbereich Herz-Kreislauf, Detmold, Germany.
Dtsch Med Wochenschr. 2007 Jul 30;132(30):1559-66. doi: 10.1055/s-2007-984934.
In hospital mortality of acute myocardial infarction (AMI) has been reduced due to the availability of better therapeutic strategies. But there is still a gap between mortality rates in randomised trials and daily clinical practice. Thus, it was aim of the present registry to document the course and outcome of patients with AMI and to improve patient care by implementing recent guidelines.
In a nationwide registry study in hospitals in Germany with a cardiology unit or an internal medicine department data on consecutive patients were recorded for six to twelve months at admission, discharge and during a follow-up of one year.
From 02/2003 until 10/2004 a total of 5,353 patients with acute myocardial infarction (65.7 % male, mean age of 67.6 +/- 17.7 years; 55.1 % of them with ST elevation myocardial infarction (STEMI) were included in the registry. Of the patients with STEMI, 76.6 % underwent acute intervention, 37.1 % had thrombolysis, 69.7 % percutaneous transluminal coronary angioplasty (PTCA). 40.0 % of those with non-Stemi (NSTEMI) had an acute intervention, 6.6 % thrombolysis, 73.5 % PTCA. Recommended secondary prevention consisted of ASS (93.2 %), beta-blockers (93.0 %), CSE-inhibitors (83.5 %), ACE-inhibitors (80.9 %) and clopidogrel (74.0 %). In-hospital mortality was 10.5 % (STEMI) and 7.4 % (NSTEMI).
The 9 % mortality among patients with acute myocardial infarction treated in the hospitals participating in the SAMI registry is low compared to that in similar collectives. The high number of patients who had thrombofibrinolysis and coronary interventions as well as the early initiation of drug therapy contributed to these results. Medical treatment in the prehospital phase of these patients remains still insufficient and to a substantial extent contributes to the mortality of acute myocardial infarction.
由于有了更好的治疗策略,急性心肌梗死(AMI)患者的院内死亡率有所降低。但随机试验中的死亡率与日常临床实践中的死亡率仍存在差距。因此,本登记研究的目的是记录AMI患者的病程和结局,并通过实施最新指南改善患者护理。
在德国设有心脏病科或内科的医院进行的一项全国性登记研究中,连续记录患者入院、出院时以及一年随访期间六至十二个月的数据。
从2003年2月至2004年10月,共有5353例急性心肌梗死患者(65.7%为男性,平均年龄67.6±17.7岁;其中55.1%为ST段抬高型心肌梗死(STEMI))被纳入登记研究。在STEMI患者中,76.6%接受了急性干预,37.1%接受了溶栓治疗,69.7%接受了经皮腔内冠状动脉成形术(PTCA)。非ST段抬高型心肌梗死(NSTEMI)患者中有40.0%接受了急性干预,6.6%接受了溶栓治疗,73.5%接受了PTCA。推荐的二级预防措施包括阿司匹林(93.2%)、β受体阻滞剂(93.0%)、他汀类抑制剂(83.5%)、血管紧张素转换酶抑制剂(80.9%)和氯吡格雷(74.0%)。院内死亡率为10.5%(STEMI)和7.4%(NSTEMI)。
与类似群体相比,参与SAMI登记研究的医院中接受治疗的急性心肌梗死患者9%的死亡率较低。大量患者接受了血栓纤维蛋白溶解和冠状动脉干预以及药物治疗的早期启动促成了这些结果。这些患者院前阶段的医疗治疗仍然不足,在很大程度上导致了急性心肌梗死的死亡率。